>>> US Gapping up

Gapping up
In reaction to earnings/guidance:
  • AIR +3.8%
Select Chinese ADRs showing strength following stimulus:
  • FUTU +8.6%, KC +8.1%, BEKE +8%, DADA +7.9%, LI +7.7%, JD +7.6%, NIO +7.4%, BILI +7.2%, XPEV +7.2%, TME +5.7%, ASHR +5.6%, BABA +5.5%, FXI +5.3%, HUYA +5.2%, WB +5%, NIU +4.8%, BIDU +4.3%, VIPS +3.7%, MLCO +3.3%, MOMO +2.3%
Select mining stocks trading higher following China's stimulus:
  • AA +5.1%, FCX +5%, ALB +4.8%, VALE +4.6%, MT +4.5%, SQM +4.4%, RIO +4.4%, BHP +4%, LAC +2.6%, CLF +2.5%, ALTM +2.4%
Other news:
  • LBRDA +21.1% (issues counterproposal to Charter Communications)
  • LWAY +16.1% (Danone (DANOY) proposes to acquire all shares of LWAY for $25/share)
  • CANF +15.2% (veterinary partner Vetbiolix exercised its option and signed a development and commercialization agreement with Can-Fite)
  • PANL +5.4% to merge vessels from M.T. Maritime Management into its fleet)
  • KSPI +3.7% (responds to investor questions)
  • ACAD +3% (names new CEO)
  • BASE +2.9% (bought 21,080 shares at $14.0766 - $14.1953 worth approx. $298K)
  • RUN +2.8% (partners with Toll Brothers (TOL) to provide solar power and storage to Toll Brothers homes)
  • LVO +2.5% (enters into distribution partnerships with SOKO and Kelly Family Distributors)
  • HES +2.3% (FTC to greenlight CVX's merger proposal)
  • ARLO +2.3% (approves $50 mln stock repurchase plan)
  • BIIB +1.7% (Biogen and UCB Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024)
  • DNN +1.7% (announces option of non-core exploration projects to foremost for up to $30 million in combined consideration)
  • FANG +1.5% (Diamondback Energy, Kinetik Holdings and EPIC Midstream announce transformative transactions for EPIC Crude; also announces the upsize and pricing of public offering of 12.77 mln shares of common stock by certain Legacy Endeavor Stockholders)
  • GFL +1.2% (offering of $210 million of tax-exempt industrial revenue bonds)
  • NVO +1.1% (treatment of transthyretin amyloidosis granted orphan designation)